Kryscio Richard J, Abner Erin L, Caban-Holt Allison, Lovell Mark, Goodman Phyllis, Darke Amy K, Yee Monica, Crowley John, Schmitt Frederick A
Sanders-Brown Center on Aging, University of Kentucky, Lexington2Alzheimer's Disease Center, University of Kentucky, Lexington3Department of Biostatistics, University of Kentucky, Lexington4Department of Statistics, University of Kentucky, Lexington.
Sanders-Brown Center on Aging, University of Kentucky, Lexington2Alzheimer's Disease Center, University of Kentucky, Lexington3Department of Biostatistics, University of Kentucky, Lexington5Department of Epidemiology, University of Kentucky, Lexington.
JAMA Neurol. 2017 May 1;74(5):567-573. doi: 10.1001/jamaneurol.2016.5778.
Oxidative stress is an established dementia pathway, but it is unknown if the use of antioxidant supplements can prevent dementia.
To determine if antioxidant supplements (vitamin E or selenium) used alone or in combination can prevent dementia in asymptomatic older men.
DESIGN, SETTING, AND PARTICIPANTS: The Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADViSE) trial began as a double-blind randomized clinical trial in May 2002, which transformed into a cohort study from September 2009 to May 2015. The PREADViSE trial was ancillary to the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized clinical trial of the same antioxidant supplements for preventing prostate cancer, which closed in 2009 owing to findings from a futility analysis. The PREADViSE trial recruited 7540 men, of whom 3786 continued into the cohort study. Participants were at least 60 years old at study entry and were enrolled at 130 SELECT sites, and Cox proportional hazards models were used in a modified intent-to-treat analysis to compare hazard rates among the study arms.
Participants were randomized to vitamin E, selenium, vitamin E and selenium, or placebo. While taking study supplements, enrolled men visited their SELECT site and were evaluated for dementia using a 2-stage screen. During the cohort study, men were contacted by telephone and assessed using an enhanced 2-stage cognitive screen. In both phases, men were encouraged to visit their physician if the screen results indicated possible cognitive impairment.
Dementia case ascertainment relied on a consensus review of the cognitive screens and medical records for men with suspected dementia who visited their physician for an evaluation or by review of all available information, including a functional assessment screen.
The mean (SD) baseline age of the 7540 participants was 67.5 (5.3) years, with 3936 (52.2%) reporting a college education or better, 754 (10.0%) reporting black race, and 505 (6.7%) reporting Hispanic ethnicity. Dementia incidence (325 of 7338 men [4.4%]) was not different among the 4 study arms. A Cox model, which adjusted incidence for participant demographic information and baseline self-reported comorbidities, yielded hazard ratios of 0.88 (95% CI, 0.64-1.20) for vitamin E, 0.83 (0.60-1.13) for selenium, and 1.00 (0.75-1.35) for the combination compared with placebo.
Neither supplement prevented dementia. To our knowledge, this is the first study to investigate the long-term association of antioxidant supplement use and dementia incidence among asymptomatic men.
氧化应激是一条已明确的痴呆症发病途径,但抗氧化剂补充剂的使用是否能预防痴呆症尚不清楚。
确定单独使用或联合使用抗氧化剂补充剂(维生素E或硒)是否能预防无症状老年男性患痴呆症。
设计、背景和参与者:维生素E和硒预防阿尔茨海默病(PREADViSE)试验始于2002年5月的一项双盲随机临床试验,2009年9月至2015年5月转变为队列研究。PREADViSE试验是硒和维生素E癌症预防试验(SELECT)的辅助试验,后者是一项使用相同抗氧化剂补充剂预防前列腺癌的随机临床试验,该试验于2009年因无效性分析结果而终止。PREADViSE试验招募了7540名男性,其中3786名继续参与队列研究。参与者在研究开始时至少60岁,在130个SELECT研究点入组,采用Cox比例风险模型进行改良意向性分析,以比较各研究组之间的风险率。
参与者被随机分为维生素E组、硒组、维生素E和硒组或安慰剂组。在服用研究补充剂期间,入组男性前往其SELECT研究点,并通过两阶段筛查评估痴呆症。在队列研究期间,通过电话联系男性,并使用强化的两阶段认知筛查进行评估。在两个阶段中,如果筛查结果表明可能存在认知障碍,均鼓励男性去看医生。
痴呆症病例的确定依赖于对认知筛查和病历的共识审查,这些病历来自因评估而去看医生的疑似痴呆症男性,或者通过审查所有可用信息,包括功能评估筛查。
7540名参与者的平均(标准差)基线年龄为67.5(5.3)岁,其中3936名(52.2%)报告接受过大学教育或更高学历,754名(10.0%)报告为黑人,505名(6.7%)报告为西班牙裔。4个研究组之间的痴呆症发病率(7338名男性中的325名[4.4%])没有差异。一个根据参与者人口统计学信息和基线自我报告的合并症调整发病率的Cox模型得出,与安慰剂相比,维生素E的风险比为0.88(95%CI,0.64 - 1.20),硒的风险比为0.8